Trained innate immunity and resistance to Mycobacterium tuberculosis infection

Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
Valerie A C M KoekenReinout van Crevel

Abstract

Some individuals, even when heavily exposed to an infectious tuberculosis patient, develop neither active nor latent tuberculosis infection (LTBI). This 'early clearance' of Mycobacterium tuberculosis is associated with a history of bacillus Calmette-Guérin (BCG) vaccination. As BCG vaccination can boost innate immune responses through a process termed 'trained immunity', we hypothesize that BCG-induced trained innate immunity contributes to early clearance of M. tuberculosis. We describe the epidemiological evidence and biological concepts of early clearance and trained immunity, and the possible relation between these two processes through BCG vaccination. Relevant data from published reports up to November 2018 were examined in the conduct of this review. Several observational studies and one recent randomized trial support the concept that boosting innate immunity contributes to protection against M. tuberculosis infection, with BCG vaccination providing approximately 50% protection. The molecular mechanisms mediating early clearance remain largely unknown, but we propose that trained immunity, characterized by epigenetic and metabolic reprogramming of innate immune cells such as monocytes or macrophages, is at least partia...Continue Reading

Associated Clinical Trials

Citations

Nov 17, 2019·The Journal of Immunology : Official Journal of the American Association of Immunologists·Anne-Sophie DebrieCamille Locht
Jan 15, 2020·International Reviews of Immunology·Yuntong LiuDongmei Yan
Nov 28, 2019·Mucosal Immunology·C YoungN Du Plessis
Jan 29, 2020·The Journal of Infectious Diseases·Bridget FreyneUNKNOWN Melbourne Infant Study: BCG for Allergy and Infection Reduction (MIS BAIR) Group
Feb 27, 2020·Seminars in Immunopathology·Katharina RöltgenCharlotte Avanzi
Apr 9, 2019·The Journal of Infectious Diseases·Ayesha J VerrallReinout van Crevel
Jun 28, 2019·Frontiers in Immunology·Rachel TannerHelen McShane
Apr 24, 2020·Frontiers in Cellular and Infection Microbiology·Abul K AzadLarry S Schlesinger
Nov 10, 2020·Frontiers in Cellular and Infection Microbiology·Simran Kaur AroraNasreen Zafar Ehtesham
Feb 3, 2021·The Journal of Clinical Investigation·W Henry BoomJacqueline M Achkar
Mar 19, 2021·Pediatric Research·Huanbin XuXiaolei Wang
Mar 16, 2021·Frontiers in Immunology·Xingyu ZhaiJianhong Lu
May 7, 2021·Immunological Reviews·Asma AhmedAnnapurna Vyakarnam
Jan 26, 2021·The Journal of Allergy and Clinical Immunology·Alisha M SmithSunil K Ahuja
Jul 2, 2021·Emerging Topics in Life Sciences·Derry K MercerDouglas Fraser-Pitt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Related Papers

The Journal of Clinical Investigation
Shabaana A KhaderBill and Melinda Gates Foundation Collaboration for TB Vaccine Discovery Innate Immunity Working Group18
Seminars in Immunology
Mihai G Netea, Reinout van Crevel
© 2022 Meta ULC. All rights reserved